Polymyalgia Rheumatica Clinical Trial
Official title:
Efficacy of Micro-pulse Steroid Therapy as Induction Therapy in Patients With Polymyalgia Rheumatica
The study will examine the efficacy of a single intramuscular injection of betamethasone dipropionate/betamethasone sodium phosphate at the dose of 20mg/8mg (injection volume 4 ml) as an induction therapy in patients with polymyalgia rheumatica. Twenty patients will be randomized to receive an injection of betamethasone or placebo (isotonic NaCl solution) immediately after diagnosis. Both groups will receive the standard-of-care steroid therapy, starting from 10 mg of prednisone every day (qd), tapered down by 2.5 mg monthly if the disease is not active (scheduled monthly follow-ups by a rheumatologist). Primary outcome measures: the total cumulative dose of glucocorticosteroids and disease duration.
n/a
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04972968 -
A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154
|
Phase 2 | |
| Active, not recruiting |
NCT04519580 -
Improved Diagnostics and Monitoring of Polymyalgia Rheumatica
|
||
| Recruiting |
NCT06460142 -
Assessing Biomarker in Giant Cell Arteritis and Polymyalgia Rheumatic
|
||
| Terminated |
NCT03600818 -
Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica
|
Phase 3 | |
| Completed |
NCT00836810 -
Timed Release Tablet Prednisone in Polymyalgia Rheumatica
|
Phase 2/Phase 3 | |
| Completed |
NCT04239521 -
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
|
||
| Completed |
NCT03263715 -
A Study to Evaluate the Efficacy of Tocilizumab as a Remission-Induction and Glucocorticoid-Sparing Regimen in Subjects With New-Onset Polymyalgia Rheumatica (PMR- SPARE)
|
Phase 3 | |
| Recruiting |
NCT05935709 -
DANIsh VASculitis Database (DANIVAS)
|
||
| Not yet recruiting |
NCT02985424 -
Polymyalgia Rheumatica and Giant Cell Arteritis
|
N/A | |
| Completed |
NCT00138983 -
Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol.
|
Phase 3 | |
| Recruiting |
NCT06130540 -
Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR
|
Phase 1 | |
| Recruiting |
NCT05767034 -
Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)
|
Phase 3 | |
| Terminated |
NCT01821040 -
A Study Assessing the Efficacy and Safety of Lodotra® Compared to Prednisone IR in Subjects Suffering From PMR
|
Phase 3 | |
| Recruiting |
NCT05312944 -
Polymyalgia Rheumatica Associated to Primary Sjogren Syndrome
|
||
| Recruiting |
NCT04664465 -
PRediction Of DIverse Glucocorticoids toxIcity OUtcomeS
|
||
| Withdrawn |
NCT02899026 -
Efficacy and Safety Study of Sirukumab in Subjects With Polymyalgia Rheumatica
|
Phase 3 | |
| Recruiting |
NCT03576794 -
Treatment With Leflunomide in Patients With Polymyalgia Rheumatica
|
Phase 3 | |
| Completed |
NCT05681676 -
Melanocortin Gene Expression in Lymphocytes of Polymyalgia Patients
|
||
| Recruiting |
NCT05435781 -
Effect of Supplemental Hydrocortisone During Stress in Prednisolone-induced Adrenal Insufficiency
|
Phase 4 | |
| Terminated |
NCT03656627 -
Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease
|
Phase 1 |